Viking Therapeutics, Inc.

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases. We aim to develop therapies that patients and physicians can utilize in a community setting. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). We believe the compelling cell killing properties of NK cells, when combined with mAbs for targeting, creates an opportunity to generate potentially transformative therapies. The Sr. Manager, Medical Writing plays a key role in supporting clinical development, regulatory submissions, and scientific communications across Artiva Biotherapeutics. Reporting to the Associate Director, Medical Writing, this individual is a capable, hands-on author of clinical and regulatory documents and a...